for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Gilead Sciences, Inc.

GILD.O

Latest Trade

74.42USD

Change

1.16(+1.58%)

Volume

10,935,937

Today's Range

73.36

 - 

74.55

52 Week Range

60.89

 - 

85.97

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
73.26
Open
74.38
Volume
10,935,937
3M AVG Volume
470.05
Today's High
74.55
Today's Low
73.36
52 Week High
85.97
52 Week Low
60.89
Shares Out (MIL)
1,254.37
Market Cap (MIL)
91,895.40
Forward P/E
11.61
Dividend (Yield %)
3.71

Next Event

Gilead Sciences Inc at Jefferies Healthcare Conference (Virtual)

Latest Developments

More

Gilead Announces Results From Phase 3 Trial Of Remdesivir In Patients With Moderate COVID-19

Galapagos: Capital Increase Of EUR 17.9 Million

Gilead Sciences And Arcus Biosciences Establish 10-Year Partnership To Co-Develop And Co-Commercialize Next-Generation Cancer Immunotherapies

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Gilead Sciences, Inc.

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.

Industry

Biotechnology & Drugs

Contact Info

333 LAKESIDE DR

FOSTER CITY, CA

94404

United States

+1.650.5743000

https://www.gilead.com/

Executive Leadership

Daniel O'Day

Chairman of the Board, Chief Executive Officer

Andrew D. Dickinson

Chief Financial Officer, Executive Vice President

Brett Alan Pletcher

Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary

Jyoti Mehra

Executive Vice President of Human Resources

Linda Higgins

Senior Vice President - Head of External Innovation

Key Stats

2.63 mean rating - 30 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

26.1K

2018

22.1K

2019

22.4K

2020(E)

22.4K
EPS (USD)

2017

8.840

2018

6.670

2019

6.630

2020(E)

6.312
Price To Earnings (TTM)
18.83
Price To Sales (TTM)
4.05
Price To Book (MRQ)
4.16
Price To Cash Flow (TTM)
14.52
Total Debt To Equity (MRQ)
109.20
LT Debt To Equity (MRQ)
100.14
Return on Investment (TTM)
9.48
Return on Equity (TTM)
8.05

Latest News

Latest News

Gilead's remdesivir could see $7 billion in annual sales on stockpiling boost: analyst

Gilead Sciences Inc's <GILD.O> potential COVID-19 treatment, remdesivir, could bring in more than $7 billion in annual sales by 2022, spurred by governments stockpiling the drug to guard against future outbreaks, SVB Leerink said on Wednesday.

India approves Gilead's remdesivir to treat severe COVID-19 cases

India's government has approved Gilead Sciences Inc's antiviral drug remdesivir for emergency use for five doses in treating COVID-19 patients.

Gilead's next step on coronavirus: inhaled remdesivir, other easier-to-use versions

Gilead Sciences Inc is developing easier-to-administer versions of its antiviral treatment remdesivir for COVID-19 that could be used outside of hospitals, including ones that can be inhaled, after trials showed moderate effectiveness for the drug given by infusion.

MEDIA-India approves Gilead's remdesivir for use in 'severe' COVID-19 cases -Indian Express

-- Note: Reuters has not verified this story and does not vouch for its accuracy (Bengaluru newsroom)

Gilead's remdesivir shows modest improvement in moderate COVID-19 patients

Gilead Sciences Inc on Monday reported that its antiviral drug remdesivir provided a modest benefit in patients with moderate COVID-19 given a five-day course of the treatment, while those who received the medicine for 10 days in the study did not fare as well.

BRIEF-Mark Genovese Joins Gilead To Lead Clinical Development Of Company's Inflammation Programs

* MARK GENOVESE JOINS GILEAD TO LEAD CLINICAL DEVELOPMENT OF COMPANY’S INFLAMMATION PROGRAMS Source text for Eikon: Further company coverage:

FACTBOX-Global pharma industry steps up efforts to battle new coronavirus

(Adds Sun Pharmaceutical, Glenmark Pharmaceuticals; updates Gilead, Novavax, Vir, Eli Lilly, Moderna, AstraZeneca, Quest) June 1 (Reuters) - Drugmakers are rushing to develop a treatment or vaccine for the fast-spreading novel coronavirus that has killed over 370,316 people...

BRIEF-Gilead Announces Results From Phase 3 Trial Of Remdesivir In Patients With Moderate COVID-19

* GILEAD ANNOUNCES RESULTS FROM PHASE 3 TRIAL OF REMDESIVIR IN PATIENTS WITH MODERATE COVID-19

Gilead says remdesivir helped moderate COVID-19 patients improve

Gilead Sciences Inc said on Monday results from a study showed its antiviral drug remdesivir demonstrated significantly greater clinical improvement in patients with moderate COVID-19.

Gilead trades that made millions on COVID-19 drug news raise eyebrows

Well-timed trades in Gilead Sciences Inc's options ahead of good news on the biopharmaceutical company's COVID-19 drug treatment may draw regulatory scrutiny, experts said.

European, South Korean authorities vie for COVID-19 antiviral remdesivir

European and South Korean authorities are vying for Gilead Sciences' potential COVID-19 treatment, remdesivir, even though the drugmaker has yet to gain regulatory approval in either market and is still ramping up production of the anti-viral drug.

European, South Korean authorities vie for COVID-19 antiviral remdesivir

European and South Korean authorities are vying for Gilead Sciences' <GILD.O> potential COVID-19 treatment, remdesivir, even though the drugmaker has yet to gain regulatory approval in either market and is still ramping up production of the anti-viral drug.

BRIEF-Investigational Magrolimab In Combination With Azacitidine Demonstrates Durable Activity In Previously-Untreated Myelodysplastic Syndrome And Acute Myeloid Leukemia

* INVESTIGATIONAL MAGROLIMAB IN COMBINATION WITH AZACITIDINE DEMONSTRATES DURABLE ACTIVITY IN PREVIOUSLY-UNTREATED MYELODYSPLASTIC SYNDROME AND ACUTE MYELOID LEUKEMIA

BRIEF-EMA Says CHMP To Conduct Speedy Review Of Remdesivir Once Application Is In

* SAYS FIRST CYCLE OF REMDESIVIR ROLLING REVIEW WAS CONCLUDED ON 15 MAY

BRIEF-Galapagos: Capital Increase Of EUR 17.9 Million

* ANNOUNCED ON THURSDAY SHARE CAPITAL INCREASE THROUGH SUBSCRIPTION RIGHT EXERCISES

South Korea seeks to import anti-viral remdesivir as new coronavirus cases emerge

South Korean health authorities said on Friday they would request imports of Gilead Sciences Inc's anti-viral drug remdesivir to treat COVID-19, as new outbreaks of the disease flare as social distancing restrictions are eased.

Gilead study shows shorter 5-day course of remdesivir works as well as 10-day one

Gilead Sciences Inc, which has suggested that a shorter treatment duration could extend limited supplies of its drug remdesivir, on Wednesday published results of a study showing no significant difference in outcomes between 5- and 10-day courses of the drug for patients...

Roche mixes Actemra with Gilead's remdesivir in COVID-19 trial

Roche plans to test if mixing its anti-inflammation drug Actemra with Gilead Sciences Inc's anti-viral treatment remdesivir works better against severe COVID-19 pneumonia than remdesivir alone, the Swiss drugmaker said on Thursday.

MEDIA-Gilead irked by India's BDR Pharma's remdesivir move without licensing pact - Economic Times

-- Note: Reuters has not verified this story and does not vouch for its accuracy (Bengaluru newsroom)

BRIEF-Gilead Sciences And Arcus Biosciences Establish 10-Year Partnership To Co-Develop And Co-Commercialize Next-Generation Cancer Immunotherapies

* GILEAD SCIENCES AND ARCUS BIOSCIENCES ESTABLISH 10-YEAR PARTNERSHIP TO CO-DEVELOP AND CO-COMMERCIALIZE NEXT-GENERATION CANCER IMMUNOTHERAPIES

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up